Leerink Partners analyst Faisal Khurshid has maintained their bullish stance on PLRX stock, giving a Buy rating on September 13. Faisal Khurshid has given his Buy rating due to a combination of ...
Undervalued: the stock is currently in the oversold territory after some investors over-reacted and sold after the Phase 2 BEXO trial, we like the FVC slow down and clean safety data. Promising ...
Tuesday, shares of Pliant Therapeutics (NASDAQ:PLRX) maintained a Buy rating from TD Cowen, following encouraging clinical trial results. The firm highlighted the positive Phase 2a 24-week ...
Hosted on MSN
Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip
Nurix Therapeutics shares fell more than 6% in after-hours trading on Thursday after the biotech firm reported a wider quarterly loss and lower revenue, reflecting higher research spending and changes ...
On Tuesday, RBC Capital maintained its Outperform rating on Pliant Therapeutics (NASDAQ:PLRX), with a steady price target of $45.00. The firm's stance comes in the wake of positive indicators from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results